Lithium Argentina

Phase A — Understand the business

Company Overview

What it actually is: a single-producing-asset lithium holding company whose economic engine is a 44.8% co-ownership of one Argentine brine operation, Cauchari-Olaroz (Jujuy province), held through the equity-accounted operating company Minera Exar S.A. ("Exar"). It is not an operator in the accounting sense — Exar is run as a JV and consolidated by Ganfeng Lithium Co., Ltd., so LAR picks up its share as equity-method income, not consolidated revenue.

Ownership stack of Cauchari-Olaroz: LAR 44.8% · Ganfeng 46.7% · JEMSE (Jujuy Energía y Minería S.E., the provincial government's mining company) 8.5%. LAR + Ganfeng together own 91.5% of Exar; economically, under the Amended Shareholders Agreement (Aug 2020), the split is Ganfeng 51% / LAR 49% of the operation's offtake and costs, with JEMSE's 8.5% a carried interest paid out of future dividends.

Product & customers: battery/technical-grade lithium carbonate. LAR is entitled to 49% of offtake ≈ 19,600 tpa at full 40,000 tpa capacity. Under offtake agreements dated Aug 27, 2020, substantially all FY2025 sales went to just two counterparties — Ganfeng (entitled to 80% of the first 12,250 tpa) and Bangchak (Thai refiner). LAR concluded it acts as agent (not principal) in these sales — control of the carbonate does not pass to LAR — so it books almost no lithium revenue on its own income statement; the economics arrive as equity pickup + finance income on loans to Exar. This is the single most important structural fact in the whole file: the headline income statement is not the business.

Second asset (development): PPG (Pozuelos–Pastos Grandes, Salta province), a New JV announced Aug 2025 that folds Ganfeng's Pozuelos–Pastos Grandes into LAR's Pastos Grandes (85%) + Sal de la Puna (65%). On close, Ganfeng 67% / LAR 33% — ownership set by "resources, capital contributions and technology inputs," i.e. LAR was diluted below its standalone asset weight because Ganfeng brings more. Target: phased up to 150,000 tpa LCE in three 50,000-tpa phases; the parties are seeking a third investor.

Corporate history in one line: Lithium Americas Corp. (renamed 2016) → acquired Millennial Lithium (Jan 2022) and Arena Minerals (Apr 2023) → Separation Transaction Oct 3, 2023 (spun off the North-American/Thacker-Pass unit = today's LAC; retained the Argentine unit) → redomiciled Canada→Switzerland ("the Continuation") as Lithium Argentina AG.

Supply Chain

Upstream → operation → customer, with names:

• Resource / feedstock: the Cauchari and Olaroz salars (brine aquifers) — LAR's own orebody; no third-party feedstock (unlike spodumene converters). 2026 reserve base 1,414,682 t P&P LCE (35-yr); M&I resource expanded +42% to ~28 Mt LCE at 562 mg/L (Mar 2026).
• Operator: Minera Exar S.A. — the equity-accounted operating co; Ganfeng consolidates and effectively runs it (Ganfeng seconds technical staff; the DLE roadmap is Ganfeng-driven). LAR's influence is contractual (shareholder committee), not operational control.
• Process inputs: soda ash, lime, reagents (biggest variable cost line), diesel, evaporation-pond infrastructure; Direct Lithium Extraction (DLE) being layered in to lift recovery/consistency. Total FY-basis operating cost per the technical report $5,411/t on a 100% basis ($216.4M total).
• Financing counterparty: Ganfeng again — it arranges the Exar bank loans (guarantees/SBLCs) and provided LAR a $130M 6-yr corporate facility (SOFR+2.5%, Mar 2026).
• Buyers: Ganfeng (majority offtake) and Bangchak. Logistics: carbonate trucked/railed out of Jujuy → port → China/Thailand.
• Government stakeholder: JEMSE (8.5% provincial carry) + the Province of Jujuy (permitting, water, social licence) + federal RIGI regime (fiscal/FX stability for Stage 2).

Chokepoints / single-source dependencies: the chain is Ganfeng at four nodes simultaneously — co-owner, operator, primary buyer, and lender. There is essentially no diversification on the sell side or the operating side. The only nodes LAR controls outright are the orebody and the balance sheet. Names present, dependency concentrated — this is a captive-partner supply chain, not an open one.

Competitive Advantages (moats)

Real, durable moat — the asset: Cauchari-Olaroz is a producing, permitted, low-cost brine at genuine scale. Q1-2026 cash cost <$5,400/t puts it "among the lowest reported for lithium chemical production globally". Brine at first-quartile cost is a 20+ year cost-curve position that spodumene converters (Pilbara, and the marginal Chinese lepidolite tonnes) cannot structurally match. In a commodity, cost-curve position is the moat — and this one is strong.

Weak moat — the corporate wrapper: LAR the equity has almost no moat around the asset. It is a minority, non-operating co-owner whose bargaining power over its dominant partner is limited: Ganfeng needs LAR's 44.8% far less than LAR needs Ganfeng's operating skill, offtake balance-sheet and capital. Switching costs run the wrong way — LAR cannot replace Ganfeng; Ganfeng could, over time, dilute or squeeze LAR (the PPG 33/67 split is the template). No brand, no network effect, no IP owned by LAR (the DLE IP sits with Ganfeng/licensors).

Net: the moat is the rock and the cost curve, not the company. You own a great asset through a structurally weak seat at the table.

Segments

No our figures and the 20-F does not run segment reporting in the conventional sense — LAR is effectively single-segment (lithium carbonate) and single-geography (Argentina). What breaks out is asset vs. asset:

Production trend (100% basis): 2023 6,000t → 2024 25,400t (commercial production achieved) → 2025 34,100t → 2026 guide 35,000–40,000t (near design cap). Ramp is essentially complete on Stage 1; the growth narrative from here is price × Stage-2 volume, not the Stage-1 ramp. Note the minor discrepancy: the business-section milestone text cites "~35,100t" for 2025 while the audited aggregate-production table and financial statements cite 34,100t — I use 34,100t as the audited figure.

---

Phase B — Measure performance

Earnings Result

FY2025 (audited, 20-F): the company reported a net loss of $75.4M attributable to shareholders (total $76.9M incl. NCI), widening sharply from a $15.2M loss in FY2024 — but this is an equity-accounting artefact, not deterioration: FY2025 was the trough of the lithium price cycle, so the equity pickup from Exar and mark-to-market/finance lines were depressed, while corporate costs (G&A, SBC $7.7M, finance costs $30.9M) and the deficit ran on. Finance income was $46.6M, finance/other costs $30.9M. Retained deficit $(745.0)M; total equity $816.9M.

Balance sheet (Dec-31-2025, $M): cash $61.1M (down from $85.5M) · receivables from purchasers $23.2M · current assets $84.7M · total assets $1,099.8M (~$1.1B) · investments in associates/JV ~$93M (Cauchari) · E&E assets $341.0M · equity-settleable convertible notes: carrying $234.2M / face $258.8M, due Jan 15, 2027.

The turn is already visible in the tape (Q1-2026, reported 2026-05-12): net income $7.5M (vs a $7.2M loss in Q1-2025), driven by a $22.1M share of income from Cauchari-Olaroz — LAR's first profitable quarter. Production 9,660t; cash cost <$5,400/t. Crucially, cash is now flowing: Cauchari-Olaroz distributed $100M YTD 2026 ($46M to LAR), and the FY2025 20-F already booked a $41.8M subsequent-event distribution to LAR.

Guidance: 2026 production 35,000–40,000t with operation-level EBITDA ~$460M at $20,000/t.

Balance-sheet flags: (1) cash burned $24.4M in FY2025 at the price trough; (2) the $258.8M convert wall in Jan-2027 is the defining near-term risk, partly addressed by the new $130M Ganfeng facility; (3) going-concern disclosure in the audited FS (see Lens 10). Market read: the stock is up ~6x off the 52-wk low ($2.09 → $12.05 range; $7.98 on 2026-07-02) — the tape has already priced the turn from "will it survive the trough" to "how much upside from here."

Earnings Calls (sentiment trend)

No transcripts/ on the shelf (foreign filer, sparse Fool/Insider-Monkey coverage), so this is ****-grounded from press releases and results commentary. The tonal arc across the last ~4 reporting cycles:

• Late-2024 / early-2025 (trough): defensive — "commercial production achieved," cost discipline, balance-sheet survival, refinancing the convert, capital-control/repatriation caveats front-and-centre. The verbs were manage, refinance, preserve.
• Q4-2025 / Q1-2026 (turn): decisively offensive — "exceptional performance," "near design capacity," "lowest-cost," first distributions, Stage-2 RIGI approval, resource +42%. The verbs became distribute, expand, approve, grow.
• What they started saying: distributions, Stage 2, RIGI, DLE, 150,000 tpa PPG. What they stopped saying: the acute going-concern / can-we-fund-the-convert framing that dominated 2025 (still disclosed in the FS, but no longer the headline).

Sentiment shift is genuine and asset-backed (cost + cash + permit are facts, not spin). The tell to watch: how they talk about the JV cash waterfall — whether Stage-2 capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. will redirect distributions away from LAR.

Comps

Read: on a look-through basis (value LAR's ~49% of Cauchari-Olaroz's ~$460M operation-EBITDA against a ~$1.34B market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth. net of the ~$260M convert) LAR screens cheap-to-fair versus SQM's 12x if you believe (a) $20k lithium holds and (b) the JV lets the cash reach shareholders — but the discount is the correct price of the minority/single-asset/Argentina/Ganfeng-control stack, not a free lunch. Never model LAR on a headline P/E; model the look-through NAV of the stake. Where I could not source a clean multiple I have written n/a rather than fabricate one.

Stock-Price Catalysts

The name is a high-beta (β 2.44) proxy on the lithium price — the 52-wk range of $2.09 → $12.05 is the whole story: a ~6x move that tracks the carbonate price off its mid-2025 trough. What actually moves LAR >5%:

• The lithium carbonate spot price (dominant driver). Battery-grade carbonate ran from ~$8,259/t (Jun-2025 trough) to ~$20,684–$24,086/t (Q1–Q2 2026). LAR's chart is essentially this series levered ~2–3x.
• Oct-3-2023 Separation — the event that created the standalone name (contrast: LAC took Thacker Pass + GM).
• Q1-2026 first-profit print + first distributions (May 2026) — confirmed the cash actually reaches the HoldCo.
• RIGI approval for Stage 2 (May 14, 2026) — de-risked the +45,000 tpa expansion; announced by Argentina's Economy Minister Caputo.
• Resource upgrade +42% to 28 Mt LCE (Mar 2026) — underwrote Stage-2 scale.
• The Jan-2027 convert maturity — a recurring overhang; the $130M Ganfeng facility (Mar 2026) partially defused it.
• Argentina macro (Milei-era FX liberalisation, IMF, capital controls) — repatriation headlines move it.

Pattern: the market reacts to (1) the commodity, (2) proof cash escapes the JV, (3) Argentina political/fiscal regime, (4) the convert. Company-specific operational beats matter less than the lithium tape.

---

Phase C — Judge people & books

Management

• CEO — Samuel Pigott (42), CEO since Mar 18, 2024. The defining fact: he was Head of Business Development at Ganfeng from Oct 2018 to Mar 2024 — LAR's chief executive came directly from its controlling JV partner, operator, primary buyer and lender. Read it two ways: bull — deep operating alignment and a direct line into the partner that runs the asset; bear — the person steering LAR's negotiating posture toward Ganfeng spent six years inside Ganfeng. On a minority-stake company this is a genuine governance question, not a footnote.
• Chair — John Kanellitsas (63), long-tenured (director since 2015), former President/Interim CEO; transitions Executive → non-Executive Chair Mar 31, 2026 — a normal de-escalation as the operating team takes hold.
• Others: CFO Alex Shulga (43); COO Mariano Chiappori (56); Alec Meikle promoted to President Jan 1, 2026 (CEO shed the President title). Lead Director George Ireland (Geologic Resource Partners) is a long-standing large holder — a resource-savvy independent voice on the board.
• Skin in the game: directors + NEOs owned 9,279,844 shares = 5.66% (Mar 6, 2026) — modest, consistent with a spun-out entity where the anchor economic party is Ganfeng, not the insiders.
• Capital-allocation history: the M&A that built this (Millennial, Arena) was done under the old Lithium Americas; the current team's record is short but rational so far — refinance the convert with cheaper Ganfeng debt, take distributions, pursue RIGI-blessed Stage-2 rather than diluting equity at trough prices. The PPG 33/67 dilution is the one allocation call bears will hammer: LAR handed operating control (and majority) of its greenfield to Ganfeng.
• Archetype: professional managers running a minority partner, not owner-founders — appropriate for the stage, but it means the controlling mind of the asset sits outside the plc.

Forensic Red Flags

Forensic lens — every figure labelled. The accounting is unusual by design and demands care:

• Equity-method + agent revenue recognition (the big one): because Exar is equity-accounted and LAR is an agent in lithium sales, the P&L is not a normal producer's P&L. The economics live in (i) share of income of associates and (ii) finance income on loans to Exar Capital. Finance income was $46.6M in FY2025 — a large slice of the "good" lines is intercompany loan interest, not operating profit. This is legitimate under IFRS but means screening tools misread the company and quality-of-earnings depends on the associate's underlying cash, which flows on a JV waterfall LAR does not solely control.
• Going-concern disclosure (audited FY2025): the FS "contain disclosure related to the Company's ability to continue as a going concernGoing concernAn auditor’s formal doubt that the company can fund itself for the next year. It is a warning about survival, not about performance. … dependent upon its ability to generate and repatriate sufficient cash flows from Cauchari-Olaroz or secure additional financing." Partly mitigated post-year-end by the $41.8M distribution and $130M Ganfeng facility, but the $258.8M convert due Jan-2027 keeps this live. This is the headline red flag.
• Critical Audit Matter — impairment of associates/JV: auditor flagged the impairment assessment of the $93M Cauchari and $183M Sal de la Puna carrying values. At trough lithium prices these carry real impairment risk; the recovery in price cuts the other way.
• Related-party density: Exar loans, Exar Capital (Netherlands financing vehicle), the Ganfeng offtake, the Ganfeng guarantees, the Ganfeng $130M facility, PGCo intra-group loans (SOFR+4.0%, later amended) — a thick web of related-party transactions with the controlling partner. All disclosed, but it means arm's-length pricing is a matter of trust in a controlled structure.
• FX / capital controls: ARS inflation, Central-Bank approval to pay dividends, export-proceeds repatriation rules — cash can be trapped or devalued in transit.
• No material weakness in ICFR was disclosed (standard clean auditor language on internal control).

Regulatory findings (required sub-section):

• SEC Litigation Releases: None. Verified via SEC EDGAR EFTS (LR) for "Lithium Argentina," 2021-07-06 → 2026-07-06.
• SEC AAERs: None over the same window.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB actions or consent decrees surfaced against Lithium Argentina/Lithium Americas (Argentina) in searches to date. The only litigation-adjacent items are ordinary emerging-market operating risks (permitting appeals, Jujuy provincial/indigenous-community dynamics common to Andean lithium) — none rising to a disclosed material proceeding.
• 10-K/20-F Item on legal proceedings: the 20-F discloses no single material litigation beyond generic contingency and Argentine-jurisdiction risk language.
• Conclusion: No material regulatory or legal enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and the FY2025 20-F as of 2026-07-06. The real "forensic" risk here is structural (equity-method + related-party + going-concern + FX), not enforcement.

---

Phase D — Project & stress-test

Forward Projection

Framing. LAR's reported EPS is a poor target because the economics are equity-method + finance income and swing on the JV waterfall. The honest projection is a look-through of LAR's ~49% economic share of Cauchari-Olaroz, driven by realized lithium price × ~19,600 tpa attributable volume − ~$5,400/t cash cost − corporate costs/interest, then a scenario on whether Stage-2 capex diverts distributions. All outputs **** with arithmetic; inputs labelled.

Attributable economics of Stage 1 (LAR ~49% of ~40,000 tpa ≈ 19,600 tpa):

These are operation-level attributable cash margins, before corporate G&A ($16M+), finance costs on the convert/facility ($25–30M), and the JV waterfall haircut (distributions can be retained for Stage-2). Net free cash to LAR shareholders is materially below these gross figures — call it roughly $120–200M base-case pre-Stage-2-diversion, which against a ~$1.34B mkt cap / ~$1.6B EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. (incl. convert) is a look-through FCF yield in the high-single to low-double digits at $18k lithium — the crux of the bull case.

EPS orientation (three years, illustrative ): with the Q1-2026 run-rate ($22.1M associate income + distributions) annualising, FY2026 could print modestly positive EPS (~$0.10–0.30) at $18–20k lithium; FY2027–2028 EPS is dominated by (a) the price path and (b) Stage-2 timing more than by share-count. Given the ~2–3x price leverage, the sensible statement is a range, not a point: FY2026 EPS ~$0.10–0.35 (base), negative in the bear, $0.40+ in the bull.

Per --watchlist rules, no our model create is logged in this loop. If promoted to a thesis, the scoreable binary to log is "LAR FY2026 reports positive full-year net income (yes/no)" — a clean, near-dated calibration marker.

Bull vs Bear

Bull case. You are buying first-quartile-cost, producing, permitted brine at the exact moment the lithium market turns from glut to deficit. The facts are hard: cash cost <$5,400/t vs realized price $20k+, first profitable quarter (Q1-26), $100M of distributions already flowing ($46M to LAR), RIGI-approved Stage-2 doubling capacity to ~85,000 tpa (LAR share), and a resource that just grew 42%. Demand is structurally re-rating — execs guide 30–40% 2026 demand growth, with energy storage + AI-data-center backup now a bigger swing factor than EVs, and Morgan Stanley/UBS both modelling a 2026 deficit. At $20k lithium the asset throws off enough to fund itself, service the convert, and start Stage-2 — a self-funding growth story on a cost curve nobody can undercut.

Bear case (permanent-impairment risks). (1) Lithium is a cycle, not a secret — the same first-quartile assets (SQM's Atacama, this brine, and Ganfeng's own tonnes) that make the bull case also make the next glut, and LAR is a 2–3x levered proxy on a price that fell ~70% into mid-2025; a re-glut takes the equity back toward the $2–4 range. (2) You do not control your own cash — the JV waterfall can retain distributions for Stage-2 capex, and Argentine capital controls/FX can trap or devalue cash in transit, so shareholders can be starved even while the operation prints EBITDA. (3) Ganfeng holds every lever — operator, majority in PPG, primary buyer, lender, and the CEO's former employer — the PPG 33/67 dilution is the proof-of-concept that minority LAR economics can be redistributed toward the controlling partner. (4) The $258.8M convert (Jan-2027) still has to be cleared without heavy dilution.

Pre-mortem (18 months out, thesis broke): lithium rolled from $20k back to ~$12k as 2025–26 supply discipline broke and Chinese lepidolite/African tonnes returned; Cauchari distributions got retained inside the JV to fund Stage-2; the convert was refinanced with equity/dilutive paper; Argentine FX tightened and a distribution got stuck; the stock round-tripped most of its 6x. None of these are exotic — each is in the 20-F risk factors verbatim.

Are multiples too high? On a look-through basis, no — arguably cheap vs SQM's 12x EV/EBITDA if $18k+ holds and cash escapes the JV. But the headline β 2.44 and the 52-wk 6x move mean a lot of the recovery is already priced; the asymmetry is far less attractive than it was at $2–4.

Contrarian view (what the market is refusing to see): the bull chorus treats LAR as "a lithium producer at $20k"; the market is under-weighting that LAR is a minority financial interest in a Ganfeng-run asset, where the controlling partner has both the incentive and every mechanism to keep more of the upside (PPG already showed it). The re-rate has been about the commodity; the next leg — up or down — will be decided by JV governance and Argentine cash mobility, which almost no one is modelling.

Devil's Advocate (short-seller)

Dismantling the bull case.

• Revenue concentration is total and captive: ~100% of sales to Ganfeng + Bangchak, and Ganfeng is also the operator/co-owner/lender. If Ganfeng's own strategy shifts (it prioritises its wholly-owned tonnes, or squeezes offtake pricing at the "agreed mechanism"), LAR has no alternative channel and limited leverage — LAR even books itself as agent, underscoring how little of the value chain it controls.
• The moat is the rock, not the equity: bulls conflate a great orebody with a great share. LAR's seat is a 44.8% non-operating minority whose bargaining power is structurally weak; the PPG 33/67 split is the tell that this can be diluted.
• Most dangerous competitor bulls underestimate — Ganfeng itself and the marginal Chinese/African tonne: not a rival to LAR's asset but to LAR's price — a wave of restarted lepidolite and African spodumene can re-glut the market that the whole thesis rests on.
• Worst capital-allocation optics: handing operating control and majority of the PPG greenfield to Ganfeng; a CEO hired straight out of the controlling partner; a related-party web (Exar loans, Ganfeng guarantees, Ganfeng facility) that makes arm's-length pricing a matter of trust.
• What must hold for today's ~$8 price: lithium stays ≥$15–18k, the JV distributes rather than retains, Argentine FX lets cash out, and the convert clears without heavy dilution. Break any one and the equity re-rates down hard.
• If growth/price disappoints 20–30%: at ~$12–14k lithium the look-through cash margin roughly halves, Stage-2 self-funding evaporates, distributions get retained, and the going-concern language snaps back to the headline — downside to the $3–5 zone is plausible, not tail.
• Single scenario that permanently impairs: a structural Argentine capital-control/nationalisation-style event (the 20-F explicitly notes historical nationalisations and no political-risk insurance) that traps or seizes the cash flows — low-probability, but catastrophic and un-hedgeable for a single-country, single-asset name.

Management Questions (ordered by information value)

1. Under the Cauchari-Olaroz shareholders' agreement, what exact conditions let the JV retain distributions for Stage-2 capex rather than pay them to owners, and what is LAR's contractual protection against being starved of cash while the operation is profitable?
2. Post the PPG 33/67 outcome, what governance rights does LAR retain to prevent further economic dilution by Ganfeng across the shared basins — and where specifically can Ganfeng act without LAR's consent?
3. Precisely how do you clear the $258.8M convert maturing Jan-2027 — cash from distributions, the $130M Ganfeng facility, new debt, or equity — and what is the maximum dilution shareholders should underwrite?
4. Given the CEO's six years at Ganfeng, what independent process governs related-party pricing (offtake, Exar loans, guarantees, the $130M facility) to ensure arm's-length terms for LAR minorities?
5. What is the realized-price mechanism in the Ganfeng/Bangchak offtake versus spot, and how much basis risk sits between "market-based" and the index?
6. What are the Stage-2 capex, funding plan, and first-production date, and how much comes from retained distributions vs external capital (incl. the PPG third investor)?
7. On Argentine FX/repatriation: how much cash is currently held in-country, what has actually cleared to the HoldCo in the last 12 months, and what is the friction/haircut?
8. What is the realistic path to removing the going-concern disclosure, and what quarterly cash-generation level clears it durably?
9. What is the DLE deployment plan and its ownership — does LAR have any IP/economic rights, or is the technology (and its upside) Ganfeng's?
10. What is the impairment sensitivity of the $93M Cauchari and $183M Sal de la Puna carrying values to a $12–14k lithium price?
11. How should investors think about JEMSE's 8.5% carry and Jujuy provincial obligations as production and distributions scale?
12. What is the all-in sustaining cost (not just cash cost) at Stage-1 steady state, and how does it move with Stage-2?
13. What capital-return policy (if any) to LAR shareholders should we expect once the convert is cleared — buybacks, dividends, or reinvestment only?
14. Who is the PPG third investor you're seeking, and what does bringing them in do to LAR's 33%?
15. What single event would most change your own view of the investment case over the next 24 months?

---